therapy

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Eli Lilly & Co. (NYSE: LLY) said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3%.The Company said..